Drugs / VLX1570
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02372240 | Apr 2015 → May 2017 | plasma cell myeloma | Vivolux AB | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VLX1570 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02372240 ↗ |
| Route | Intravenous | “VLX1570 intravenous (IV) infusion” NCT02372240 ↗ |